BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an underwritten public offering of approximately 13.6 million shares of its common stock, offered at a price of $4.05 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $55.0 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 2.0 million additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about February 17, 2015, subject to the satisfaction of customary closing conditions.
Cowen and Company and Stifel are acting as joint book-running managers for the offering and Guggenheim Securities is acting as co-manager for the offering.
TherapeuticsMD has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission, or SEC, relating to the public offering of the shares of common stock described above. Before buying any shares of TherapeuticsMD’s common stock in the offering, you should carefully read the prospectus supplement and the accompanying prospectus, together with the information incorporated therein. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Alternatively, you may request the prospectus supplement and accompanying prospectus by contacting Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806 or by faxing (631) 254-7140, or Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by calling (415) 364-2720 or by emailing firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented SYMBODA™ technology platform, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics under the vitaMedMD® and BocaGreenMD® brands.
vitaMedMD®, BocaGreenMD® and TherapeuticsMD® are registered trademarks of TherapeuticsMD.
Forward Looking Statements
This press release by TherapeuticsMD Inc. may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that TherapeuticsMD intends, expects, projects, believes or anticipates will or may occur in the future. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering, risks and uncertainties associated with TherapeuticsMD’s business and finances in general and other risks described in the sections titled “Risk Factors” in TherapeuticsMD’s filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K. Forward-looking statements in this press release are made as of the date of this press release, and TherapeuticsMD undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise.